Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bimi International Medical Inc (BIMI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/16/2025: BIMI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.67% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.49M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) - | Beta -0.54 | 52 Weeks Range 0.00 - 1.65 | Updated Date 06/29/2025 |
52 Weeks Range 0.00 - 1.65 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -83.2% | Operating Margin (TTM) -124.83% |
Management Effectiveness
Return on Assets (TTM) -13.01% | Return on Equity (TTM) -103.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3477339 | Price to Sales(TTM) 0.04 |
Enterprise Value 3477339 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -2.66 | Shares Outstanding 13960700 | Shares Floating 1484160 |
Shares Outstanding 13960700 | Shares Floating 1484160 | ||
Percent Insiders 93.51 | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bimi International Medical Inc
Company Overview
History and Background
Bimi International Medical Inc., formerly known as Bimi Inc, focuses on providing healthcare products and services. It has evolved through strategic acquisitions and partnerships, mainly operating in China's healthcare market. Specific founding year details are unavailable.
Core Business Areas
- Healthcare Products Distribution: Distribution of medical devices, equipment, and healthcare-related products.
- Healthcare Services: Provision of medical consultation, diagnostics, and related healthcare services through its network.
Leadership and Structure
Leadership details, including the CEO and key executives, and the specific organizational structure are not readily and reliably available. General information suggest a structure with management teams overseeing various business segments.
Top Products and Market Share
Key Offerings
- Medical Devices: Distribution of various medical devices. Market share and revenue contribution are not publicly available. Competitors include larger multinational medical device distributors and manufacturers in China, such as Medtronic (MDT) and Siemens Healthineers (not directly traded on US stock exchanges).
- Healthcare Products: Provision of a range of healthcare products. Market share and revenue contribution are not publicly available. Competitors are other local distributors and online retailers.
Market Dynamics
Industry Overview
The healthcare industry in China is experiencing significant growth driven by an aging population, increasing healthcare awareness, and government initiatives to improve healthcare access. It is also impacted by regulatory changes and shifts towards domestic production.
Positioning
Bimi International Medical Inc. aims to position itself as a key player in the Chinese healthcare market through distribution and service offerings. Competitive advantages are unclear due to limited public information. The size is considered as a disadvantage compared to larger international companies.
Total Addressable Market (TAM)
The TAM for healthcare products and services in China is substantial and growing rapidly, estimated to be in the hundreds of billions of dollars. Bimi's positioning relative to the TAM is difficult to assess without specific market share data.
Upturn SWOT Analysis
Strengths
- Established distribution network (potentially within specific regions)
- Focus on the Chinese healthcare market
- Potential for growth in a growing market
Weaknesses
- Limited financial resources compared to larger competitors
- Lack of significant brand recognition
- High dependence on the Chinese market
- Limited available information about the company's current operations and financial state.
Opportunities
- Expansion into new geographic areas within China
- Acquisition of smaller healthcare businesses
- Partnerships with larger international healthcare companies
- Increased demand for healthcare products and services in China
Threats
- Increased competition from larger domestic and international players
- Changing government regulations and policies
- Economic slowdown in China
- Fluctuations in currency exchange rates
Competitors and Market Share
Key Competitors
- MDT
- BSX
- JNJ
Competitive Landscape
Bimi International Medical Inc faces significant challenges in competing with larger, more established players in the healthcare market. Its lack of scale and brand recognition are major disadvantages.
Growth Trajectory and Initiatives
Historical Growth: Insufficient data to evaluate historical growth trends.
Future Projections: No reliable projections are available due to limited information.
Recent Initiatives: Recent strategic initiatives are not readily available.
Summary
Bimi International Medical Inc. operates in China's growing healthcare market. However, it faces significant competition from larger, more established companies. The availability of financial information is limited, making it difficult to assess the company's financial health and growth potential. Bimi needs to improve its brand recognition and build strategic partnerships to succeed in the long term.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (limited availability)
- Company Website
- Industry Reports
Disclaimers:
The information provided is based on publicly available sources and may not be complete or accurate. This analysis is for informational purposes only and should not be considered investment advice. There is limited financial information available for this company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bimi International Medical Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-10-18 | CEO & Director Mr. Tiewei Song | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 296 | Website https://usbimi.com |
Full time employees 296 | Website https://usbimi.com | ||
BIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services; and operates two private hospitals in China. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024. BIMI Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.